SCHEMBL30786124

SCHEMBL30786124

CCNC(=O)c1cccc(F)c1S

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 1/20 0.43
HPGD P15428 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC2 Q92769 1/20 0.41
CXCR2 P25025 1/20 0.41
BRD4 O60885 2/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
F2R P25116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30739831 0.83 CES2 (0.55) L3MBTL1KMT2AGAANPC1RAB9A
SCHEMBL744426 0.82 GAA (0.63) KMT2AGAANPC1RAB9AHPGD
SCHEMBL30621479 0.82 GAA (0.63) KMT2AGAANPC1RAB9AHPGD
SCHEMBL15265662 0.81 HPGD (0.46) L3MBTL1KMT2ANPC1RAB9AHPGD
SCHEMBL30786087 0.81 GAA (0.67) KMT2AGAANPC1RAB9AHPGD
SCHEMBL30786110 0.81 GAA (0.67) KMT2AGAANPC1RAB9AHPGD
SCHEMBL30786093 0.80 CTSS (0.44) L3MBTL1KMT2AALDH1A1TSHRHTT
SCHEMBL2062047 0.80 L3MBTL1 (0.43) L3MBTL1KMT2AGAANPC1RAB9A
SCHEMBL7223289 0.78 HPGD (0.41) L3MBTL1KMT2AGAANPC1RAB9A
SCHEMBL30739874 0.78 HPGD (0.49) L3MBTL1KMT2ANPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
WO-2025082316-A1 OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州必扬医药科技有限公司 2025-04-24 WO disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 L3MBTL1 607/4885KMT2A 3866/4885GAA 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.